SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:b5758794-634a-4c4e-8c78-8172388a72f1"
 

Search: onr:"swepub:oai:lup.lub.lu.se:b5758794-634a-4c4e-8c78-8172388a72f1" > Incidence of Cancer...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Green, Anders (author)

Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial.

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • Elsevier BV,2014

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:b5758794-634a-4c4e-8c78-8172388a72f1
  • https://lup.lub.lu.se/record/4738759URI
  • https://doi.org/10.1016/j.amjcard.2014.08.016DOI
  • https://gup.ub.gu.se/publication/203715URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) clinical trial, including 1,873 patients found an increased risk for cancer with lipid-lowering therapy with ezetimibe/simvastatin 10/40 mg/day, relative to placebo. In a registry-based follow-up study over 21 months from the conclusion of the SEAS trial, new incident cancer and total mortality were investigated in the SEAS study cohort from Denmark, Finland, Norway, Sweden, and the United Kingdom. Among 1,359 subjects eligible for follow-up (73% of the original total cohort), 1,194 had no history of cancer (primary follow-up cohort). New cancers and deaths were identified in the national cancer and mortality registries and classified by an Expert Review Committee. Data were analyzed using Cox proportional-hazards models of new cancers and mortality during follow-up according to treatment group assigned in the SEAS base study and with age, gender, smoking history, and previous cancers as covariates. The primary follow-up cohort had 12 patients with new cancers in the ezetimibe/simvastatin group and 22 in the placebo group (hazard ratio 0.55, 95% confidence interval 0.27 to 1.11), indicating no significant difference between the treatment groups. During follow-up, 43 patients assigned to ezetimibe/simvastatin and 33 assigned to placebo died (hazard ratio 1.29, 95% confidence interval 0.82 to 2.03). In conclusion, in this registry-based observational follow-up study of the original SEAS study patient population, treatment with ezetimibe/simvastatin was not associated with an increased risk for cancer or mortality in the 21-month period after the completion of the original SEAS study.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ramey, Dena Rosen (author)
  • Emneus, Martha (author)
  • Iachina, Maria (author)
  • Stavem, Knut (author)
  • Bolin, KristianGothenburg University,Göteborgs universitet,Centrum för hälsoekonomi (CHEGU),Centre for Health Economics(Swepub:gu)xbolkr (author)
  • McNally, Richard (author)
  • Busch-Sørensen, Michael (author)
  • Willenheimer, RonnieLund University,Lunds universitet,Kardiologiska klinikens forskargrupp,Forskargrupper vid Lunds universitet,Cardiology Research Group,Lund University Research Groups(Swepub:lu)medf-rw0 (author)
  • Egstrup, Kenneth (author)
  • Kesäniemi, Y Antero (author)
  • Ray, Simon (author)
  • Basta, Nermine (author)
  • Kent, Christi (author)
  • Pedersen, Terje R (author)
  • Göteborgs universitetCentrum för hälsoekonomi (CHEGU) (creator_code:org_t)

Related titles

  • In:American Journal of Cardiology: Elsevier BV114:10, s. 1518-15221879-19130002-9149

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view